Header Logo

Connection

THOMAS KOSTEN to Psychiatric Status Rating Scales

Back to Details
This is a "connection" page, showing publications THOMAS KOSTEN has written about Psychiatric Status Rating Scales.
THOMAS KOSTEN
Connection Strength
1.874
Psychiatric Status Rating Scales
  1. Socio-demographic and clinical characteristics of heavy and non-heavy smokers among schizophrenia inpatients in a Chinese Han population. Psychopharmacology (Berl). 2014 Jan; 231(1):305-14.
    View in: PubMed
    Score: 0.080
  2. Prevalence, demographic and clinical correlates of suicide attempts in Chinese medicated chronic inpatients with schizophrenia. J Psychiatr Res. 2013 Oct; 47(10):1370-5.
    View in: PubMed
    Score: 0.080
  3. Clinical symptoms and cognitive impairment associated with male schizophrenia relate to plasma manganese superoxide dismutase activity: a case-control study. J Psychiatr Res. 2013 Aug; 47(8):1049-53.
    View in: PubMed
    Score: 0.079
  4. Association of functional dopamine-beta-hydroxylase (DBH) 19 bp insertion/deletion polymorphism with smoking severity in male schizophrenic smokers. Schizophr Res. 2012 Oct; 141(1):48-53.
    View in: PubMed
    Score: 0.075
  5. Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients. J Clin Psychiatry. 2012 Jul; 73(7):1025-33.
    View in: PubMed
    Score: 0.074
  6. Cigarette smoking and cognitive function in Chinese male schizophrenia: a case-control study. PLoS One. 2012; 7(5):e36563.
    View in: PubMed
    Score: 0.074
  7. Plasma total antioxidant status and cognitive impairments in schizophrenia. Schizophr Res. 2012 Aug; 139(1-3):66-72.
    View in: PubMed
    Score: 0.074
  8. Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. Psychopharmacology (Berl). 2012 Jul; 222(2):277-84.
    View in: PubMed
    Score: 0.072
  9. Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms. Addiction. 2012 Jan; 107(1):131-41.
    View in: PubMed
    Score: 0.071
  10. Smoking and tardive dyskinesia in male patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15; 35(7):1765-9.
    View in: PubMed
    Score: 0.069
  11. The SCID: a clinical instrument for assessing psychiatric disorders. NIDA Res Monogr. 1990; 105:213-9.
    View in: PubMed
    Score: 0.063
  12. The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients. Schizophr Res. 2009 Sep; 113(2-3):151-7.
    View in: PubMed
    Score: 0.060
  13. Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics. Psychopharmacology (Berl). 2008 Dec; 201(3):383-9.
    View in: PubMed
    Score: 0.057
  14. BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology. 2008 Aug; 33(9):2200-5.
    View in: PubMed
    Score: 0.054
  15. Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia. Neuropsychopharmacology. 2007 Sep; 32(9):2020-4.
    View in: PubMed
    Score: 0.051
  16. Performance of cocaine dependent individuals and controls on a response inhibition task with varying levels of difficulty. Am J Drug Alcohol Abuse. 2007; 33(5):717-26.
    View in: PubMed
    Score: 0.051
  17. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry. 2006 Feb; 63(2):219-28.
    View in: PubMed
    Score: 0.048
  18. A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-na?ve first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms. Neuropsychopharmacology. 2024 Apr; 49(5):893-902.
    View in: PubMed
    Score: 0.041
  19. Concurrent validity of the addiction severity index. J Nerv Ment Dis. 1983 Oct; 171(10):606-10.
    View in: PubMed
    Score: 0.041
  20. Comorbid major depressive disorder as a prognostic factor in cocaine-abusing buprenorphine-maintained patients treated with desipramine and contingency management. Am J Drug Alcohol Abuse. 2003 Aug; 29(3):497-514.
    View in: PubMed
    Score: 0.040
  21. Low-Dose Ziprasidone in Combination with Sertraline for First-Episode Drug-Na?ve Patients with Schizophrenia: a Randomized Controlled Trial. Neurotherapeutics. 2022 04; 19(3):1037-1046.
    View in: PubMed
    Score: 0.037
  22. Sensory gating and psychosis vulnerability in cocaine-dependent individuals: preliminary data. Biol Psychiatry. 2002 Apr 15; 51(8):683-6.
    View in: PubMed
    Score: 0.037
  23. Thrice-weekly versus daily buprenorphine maintenance. Biol Psychiatry. 2000 Jun 15; 47(12):1072-9.
    View in: PubMed
    Score: 0.032
  24. Smoking and Serum Lipid Profiles in Schizophrenia. Neurosci Bull. 2016 Aug; 32(4):383-8.
    View in: PubMed
    Score: 0.024
  25. Serum IL-18 level, clinical symptoms and IL-18-607A/C polymorphism among chronic patients with schizophrenia in a Chinese Han population. Psychoneuroendocrinology. 2016 06; 68:140-7.
    View in: PubMed
    Score: 0.024
  26. Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biol Psychiatry. 1993 Jul 1-15; 34(1-2):66-74.
    View in: PubMed
    Score: 0.020
  27. Association between DBH 19 bp insertion/deletion polymorphism and cognition in first-episode schizophrenic patients. Schizophr Res. 2013 Jul; 147(2-3):236-40.
    View in: PubMed
    Score: 0.020
  28. Association of the dopamine ?-hydroxylase 19 bp insertion/deletion polymorphism with positive symptoms but not tardive dyskinesia in schizophrenia. Hum Psychopharmacol. 2013 May; 28(3):230-7.
    View in: PubMed
    Score: 0.020
  29. Gender differences in cognitive function of patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Dec 03; 39(2):358-63.
    View in: PubMed
    Score: 0.019
  30. Elevated interleukin-18 serum levels in chronic schizophrenia: Association with psychopathology. J Psychiatr Res. 2012 Aug; 46(8):1093-8.
    View in: PubMed
    Score: 0.018
  31. The dopamine b-hydroxylase 19 bp insertion/deletion polymorphism was associated with first-episode but not medicated chronic schizophrenia. J Psychiatr Res. 2012 Jun; 46(6):733-7.
    View in: PubMed
    Score: 0.018
  32. The prevalence and clinical-demographic correlates of diabetes mellitus in chronic schizophrenic patients receiving clozapine. Hum Psychopharmacol. 2011 Aug; 26(6):392-6.
    View in: PubMed
    Score: 0.017
  33. Decreased serum brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia. Neurosci Lett. 2011 Sep 08; 502(1):37-40.
    View in: PubMed
    Score: 0.017
  34. Gender differences in the specificity of alcoholism transmission among the relatives of opioid addicts. J Nerv Ment Dis. 1991 Jul; 179(7):392-400.
    View in: PubMed
    Score: 0.017
  35. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis. 1991 Jun; 179(6):366-70.
    View in: PubMed
    Score: 0.017
  36. Performance-based assessment of functional skills in severe mental illness: results of a large-scale study in China. J Psychiatr Res. 2011 Aug; 45(8):1089-94.
    View in: PubMed
    Score: 0.017
  37. Depression as a prognostic factor for pharmacological treatment of cocaine dependence. Psychopharmacol Bull. 1991; 27(3):337-43.
    View in: PubMed
    Score: 0.017
  38. The dexamethasone suppression test and thyrotropin-releasing hormone stimulation test in posttraumatic stress disorder. Biol Psychiatry. 1990 Oct 15; 28(8):657-64.
    View in: PubMed
    Score: 0.017
  39. Reduced status of plasma total antioxidant capacity in schizophrenia with tardive dyskinesia. J Psychiatr Res. 2010 Nov; 44(15):1111-2.
    View in: PubMed
    Score: 0.016
  40. Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2010 May 30; 34(4):692-6.
    View in: PubMed
    Score: 0.016
  41. Mazindol treatment of cocaine abuse. A double-blind investigation. NIDA Res Monogr. 1990; 105:514.
    View in: PubMed
    Score: 0.016
  42. Decreased levels of serum brain-derived neurotrophic factor in drug-na?ve first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl). 2009 Dec; 207(3):375-80.
    View in: PubMed
    Score: 0.015
  43. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Nov 13; 33(8):1508-12.
    View in: PubMed
    Score: 0.015
  44. Time-dependent neuroendocrine alterations and drug craving during the first month of abstinence in heroin addicts. Am J Drug Alcohol Abuse. 2009; 35(5):267-72.
    View in: PubMed
    Score: 0.015
  45. Naloxone challenge as a biological predictor of treatment outcome in opiate addicts. Am J Drug Alcohol Abuse. 1989; 15(4):355-66.
    View in: PubMed
    Score: 0.015
  46. Severity of precipitated opiate withdrawal predicts drug dependence by DSM-III-R criteria. Am J Drug Alcohol Abuse. 1989; 15(3):237-50.
    View in: PubMed
    Score: 0.015
  47. Elevated serum levels of tumor necrosis factor-alpha in clozapine-associated obesity in chronic schizophrenia. Schizophr Res. 2008 Dec; 106(2-3):367-8.
    View in: PubMed
    Score: 0.014
  48. Diurnal variation in cue-induced responses among protracted abstinent heroin users. Pharmacol Biochem Behav. 2009 Jan; 91(3):468-72.
    View in: PubMed
    Score: 0.014
  49. Antecedents and consequences of cocaine abuse among opioid addicts. A 2.5-year follow-up. J Nerv Ment Dis. 1988 Mar; 176(3):176-81.
    View in: PubMed
    Score: 0.014
  50. Substance-use disorders in DSM-III-R. Evidence for the dependence syndrome across different psychoactive substances. Br J Psychiatry. 1987 Dec; 151:834-43.
    View in: PubMed
    Score: 0.014
  51. A 2.5-year follow-up of cocaine use among treated opioid addicts. Have our treatments helped? Arch Gen Psychiatry. 1987 Mar; 44(3):281-4.
    View in: PubMed
    Score: 0.013
  52. Parental alcoholism in opioid addicts. J Nerv Ment Dis. 1985 Aug; 173(8):461-9.
    View in: PubMed
    Score: 0.012
  53. Relationship of depression to psychosocial stressors in heroin addicts. J Nerv Ment Dis. 1983 Feb; 171(2):97-104.
    View in: PubMed
    Score: 0.010
  54. When is less treatment better? The role of social anxiety in matching methadone patients to psychosocial treatments. J Consult Clin Psychol. 1998 Dec; 66(6):924-31.
    View in: PubMed
    Score: 0.007
  55. Should protracted withdrawal from drugs be included in DSM-IV? Am J Psychiatry. 1993 May; 150(5):695-704.
    View in: PubMed
    Score: 0.005
  56. Psychiatric disorders in relatives of probands with opiate addiction. Arch Gen Psychiatry. 1991 Jan; 48(1):33-42.
    View in: PubMed
    Score: 0.004
  57. A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder. Am J Psychiatry. 1988 Oct; 145(10):1289-91.
    View in: PubMed
    Score: 0.004
  58. A field trial of DSM-III-R psychoactive substance dependence disorders. Am J Psychiatry. 1987 Mar; 144(3):351-5.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.